Genzyme, Isis in $325 million cardio drug pact

Share this article:
Genzyme has entered into a $325 million licensing deal with Isis Pharmaceuticals to commercialize mipomersen, Isis' lipid-lowering treatment for high-risk cardiovascular patients.

Mipomersen is in Phase III clinical trials for the treatment of familial hypercholesterolemia, a genetic disease that inhibits the body's ability to metabolize low-density lipoprotein cholesterol.

About 10,000 people worldwide have the condition, which can cause heart attacks in patients as young as nine-years-old. Isis expects to file for approval of the drug in 2009, the companies said in a statement.

“We had interest from many large companies and small companies,” Isis CEO Stanley Crooke said in a Bloomberg News report. “We're going to target this product to a select group of physicians and patients, and Genzyme is perfect for that. It's what they do for a living.”

Genzyme will pay Isis $150 million to purchase five million shares of Isis common stock for $30 per share. Upon completion of final contracts, Genzyme will pay Isis a $175 million up-front mipomersen license fee. In addition to this initial $325 million, Isis has the potential to receive significant milestone payments for mipomersen. Once the product is launched, the two companies will share profits.

After the drug is approved for familial hypercholesterolemia, the companies hope to gain expanded approval for about 10 million patients who have one malfunctioning copy of the gene, Crooke added.
Mipomersen pricing will be based on “appropriate value for patients with an unmet medical need,” Crooke added.

Genzyme is known for selling some of the world's most expensive medicines for rare genetic disorders.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...